ARA-290
11-amino-acid innate repair receptor (IRR) agonist derived from erythropoietin helix-B
ARA-290 (cibinetide) is an 11-amino-acid peptide modeled on the helix-B region of erythropoietin. It selectively engages the innate repair receptor without stimulating red-cell production, and has been studied for neuropathic pain and tissue protection, notably in sarcoidosis-related small-fiber neuropathy. It is investigational.
Mechanism under study
Activates the innate repair receptor (a heteromer of the EPO receptor and the beta-common receptor, CD131) to trigger anti-inflammatory and tissue-protective signaling, without the erythropoietic or prothrombotic effects of full-length erythropoietin. Studied for restoring small-nerve-fiber function and reducing neuropathic pain.
Research-reported dosing
Clinical trials have used subcutaneous cibinetide commonly around 4 mg per day for about 28 days in small-fiber neuropathy research, with related regimens explored. Investigational; not an approved drug.
4 mg vial + 2 mL bacteriostatic water = 2,000 mcg/mL (2 mg/mL); 1 unit is approximately 0.02 mg (20 mcg). A 2 mg vial + 1 mL bacteriostatic water yields the same 2 mg/mL.
Open this mix in the calculator →Dosing figures describe how this compound appears in the research literature and research-community references. They are not a recommendation for human use.
ARA-290 FAQ
What is ARA-290?
ARA-290 (cibinetide) is an 11-amino-acid peptide modeled on the helix-B region of erythropoietin. It selectively engages the innate repair receptor without stimulating red-cell production, and has been studied for neuropathic pain and tissue protection, notably in sarcoidosis-related small-fiber neuropathy. It is investigational.
What is the half-life of ARA-290?
Very short in plasma - reported on the order of minutes - although downstream tissue-protective effects are studied over a longer window.
What is the research-reported dosing for ARA-290?
Clinical trials have used subcutaneous cibinetide commonly around 4 mg per day for about 28 days in small-fiber neuropathy research, with related regimens explored. Investigational; not an approved drug.
How is ARA-290 reconstituted?
4 mg vial + 2 mL bacteriostatic water = 2,000 mcg/mL (2 mg/mL); 1 unit is approximately 0.02 mg (20 mcg). A 2 mg vial + 1 mL bacteriostatic water yields the same 2 mg/mL.
Is ARA-290 FDA-approved?
ARA-290 has an approved status in at least one context — see the overview above for the specific brand, region, and indication. Research-grade material sold separately is for laboratory use only.
References
Related peptides
BPC-157
Synthetic pentadecapeptide
A stable synthetic peptide based on a partial sequence identified in gastric juice. It is one of the most-studied research peptides for connective-tissue and gut-lining repair in animal models.
TB-500
Synthetic actin-binding peptide fragment
A synthetic fragment related to Thymosin Beta-4, a naturally occurring actin-regulating peptide. Studied in preclinical models for cell migration, wound healing, and flexibility.
Thymosin Beta-4
43-amino-acid actin-sequestering peptide (full-length thymosin beta-4)
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide and a major intracellular actin-sequestering molecule. It is the full-length parent from which the research fragment commonly sold as TB-500 is derived, and it is studied for tissue repair, angiogenesis, and cell migration. It remains investigational.